疱疹病毒治疗性疫苗研究进展

疱疹病毒感染极为普遍,可表现为原发性、潜伏性或复发性感染,几乎能在所有的动物中建立潜伏感染,且潜伏感染期间病毒保持休眠状态,宿主不表现出任何临床症状,机体在受到一些应激后,潜伏的病毒被重新激活,使机体引起复发性感染。目前预防性疫苗免疫接种仍是预防疱疹病毒感染和控制其相应疾病流行的有效手段,然而免疫接种后机体免疫系统虽能够控制感染,但却未能防止机体发生复发性感染并不能提供全面的保护。治疗性疫苗能清除潜伏感染或阻止复发性感染,可以有效地控制此类疾病的复发。因此,接种治疗性疫苗是未来防控和净化疱疹病毒的一种可行策略。本文针对在研的疱疹病毒HSV、EBV治疗性疫苗的研究进展进行综述,旨在为其余疱疹病毒治疗性疫苗的研发拓展思路。

Research progress in a therapeutic vaccine against herpes virus

Herpes virus infection is very common and can manifest as primary,latent or recurrent infection.This virus can establish latent infection in almost all animals.During latent infection,the virus remains dormant,and the host does not show any clinical symptoms.After a stress stimulus,the latent virus is reactivated,thus causing recurrent infection.Prophylactic vaccination remains an effective way to prevent herpes virus infection and control the epidemic of its corresponding diseases.However,although the immune system can control the infection after vaccination,it cannot prevent the recurrence of infection and provide comprehensive protection.A therapeutic vaccine could eliminate latent infection or prevent recurrent infection,thus effectively controlling the recurrence of such diseases.Therefore,vaccination is a feasible strategy for the prevention and control of herpes virus in the future.In this article,the research progress on herpes virus HSV and EBV therapeutic vaccines is reviewed,with an aim to expand the horizons for the development of other herpes virus therapeutic vaccines.